Get the Stockscreener App
6.85
7.31%
-0.54
Gh Research Plc stock is traded at $6.85, with a volume of 76,446.
It is down -7.31% in the last 24 hours and down -37.44% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
See More
Previous Close:
$7.39
Open:
$7.4
24h Volume:
76,446
Relative Volume:
1.19
Market Cap:
$356.39M
Revenue:
-
Net Income/Loss:
$-32.32M
P/E Ratio:
-9.9709
EPS:
-0.687
Net Cash Flow:
$-36.14M
1W Performance:
-11.50%
1M Performance:
-37.44%
6M Performance:
-41.10%
1Y Performance:
+28.76%
1-Day Range:
$6.72
$7.63
1-Week Range:
$6.72
$8.91
52-Week Range:
$5.08
$14.99
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
6.85 | 356.39M | 0 | -32.32M | -36.14M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
Fmr LLC Boosts Stake in Vodafone Group Public Limited (NASDAQ:VOD) - Defense World
Fmr LLC Trims Holdings in GH Research PLC (NASDAQ:GHRS) - MarketBeat
3 Top Cybersecurity Stock Picks for 2025 - Head Topics
GH Research PLC Attends Key Neuropsychopharmacology Conference - TipRanks
RA Capital Management L.P. Has $44.73 Million Stock Position in GH Research PLC (NASDAQ:GHRS) - MarketBeat
GH Research PLC (NASDAQ:GHRS) Shares Sold by Verition Fund Management LLC - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Down 0.3%What's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 2%Should You Buy? - MarketBeat
GH Research (NASDAQ:GHRS) Trading Down 0.8%Here's What Happened - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 1.4%Here's Why - MarketBeat
GH Research’s (GHRS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
(GHRS) Technical Data - Stock Traders Daily
HC Wainwright Reduces Earnings Estimates for GH Research - Defense World
GH Research (NASDAQ:GHRS) Shares Down 5.1%What's Next? - MarketBeat
FY2024 EPS Estimates for GH Research Cut by HC Wainwright - MarketBeat
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? - MSN
GH Research (NASDAQ:GHRS) Trading Down 1.7%Here's What Happened - MarketBeat
H.C. Wainwright maintains buy rating on GHRS shares, cites Q3 report By Investing.com - Investing.com South Africa
H.C. Wainwright maintains buy rating on GHRS shares, cites Q3 report - Investing.com Canada
3 Fast-Growing Stocks Analysts See Doubling in Price - MSN
GH Research (NASDAQ:GHRS) Trading Up 2%Time to Buy? - MarketBeat
Health Stocks Slide as Trump Picks Industry Skeptic Kennedy - MSN
HC Wainwright Reiterates "Buy" Rating for GH Research (NASDAQ:GHRS) - MarketBeat
Canaccord Genuity Group Issues Pessimistic Forecast for GH Research (NASDAQ:GHRS) Stock Price - Defense World
GH Research Q3 2024 Results and Clinical Updates - TipRanks
GH Research (NASDAQ:GHRS) Trading 1.2% HigherTime to Buy? - MarketBeat
Short Interest in GH Research PLC (NASDAQ:GHRS) Increases By 7.3% - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 3.3%Here's Why - MarketBeat
GH Research shares hold Buy rating as Canaccord anticipates pivotal durability data in 2025 - Investing.com Nigeria
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
GH Research (NASDAQ:GHRS) Stock Price Up 0.1%Time to Buy? - MarketBeat
RA Capital Management, L.P. Increases Stake in GH Research PLC - GuruFocus.com
GH Research reports deeper losses as DMT clinical trial costs mount - Green Market Report
GH Research (NASDAQ:GHRS) Shares Up 0.2%Here's What Happened - MarketBeat
Lynx1 Capital Management LP's Strategic Acquisition in GH Resear - GuruFocus.com
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
GH Research Completes Phase 2b Depression Trial Enrollment, Reports $12.1M Q3 Loss | GHRS Stock News - StockTitan
GH Research (NASDAQ:GHRS) Stock Price Up 3.8%Here's Why - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 4.1%Still a Buy? - MarketBeat
(GHRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
GH Research (NASDAQ:GHRS) Trading 3.1% HigherHere's What Happened - MarketBeat
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):